Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469528 | 1.00 | NTRK1 (0.58) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL20696083 | 0.87 | MEN1 (0.54) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL20127264 | 0.86 | POLB (0.53) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL20707615 | 0.86 | L3MBTL1 (0.51) | NTRK1POLBMAPTLMNAELANE | |
| SCHEMBL20696073 | 0.86 | MEN1 (0.53) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL11684129 | 0.83 | NTRK1 (0.51) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL11828549 | 0.83 | TDP1 (0.49) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL31336414 | 0.82 | POLB (0.50) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL9816137 | 0.82 | NTRK1 (0.47) | NTRK1POLBMAPTLMNAHTT | |
| SCHEMBL4920989 | 0.81 | POLB (0.49) | NTRK1POLBMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635490-B1 | Process for the preparation of N-ethylcarbazole | HOECHST AG (DE) | 1996-12-11 | — | — | EP | claimed |
| US-5393894-A | Process for the preparation of N-ethylcarbazole | CASSELLA AKTIENGESELLSCHAFT (DE) | 1995-02-28 | — | — | US | claimed |
| EP-0635490-A1 | Process for the preparation of N-ethylcarbazole | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-01-25 | — | — | EP | claimed |
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | 7 HILLS PHARMA INC. | 2024-10-08 | — | — | US | disclosed |
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2022-04-21 | — | — | US | disclosed |
| CN-110058344-A | Optical film | 住友化学株式会社 | 2019-07-26 | — | — | CN | disclosed |
| CN-104977644-B | Polarization plates and liquid crystal display panel | 东友精细化工有限公司 | 2019-06-07 | — | — | CN | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3438077-A1 | PROCESS FOR DEOXYFLUORINATION OF PHENOLS | Studiengesellschaft Kohle mbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| CN-104345374-B | Optical film | 住友化学株式会社 | 2018-12-21 | — | — | CN | disclosed |
| CN-101479310-B | Amine imide compound to be activated by irradiation of active energy ray, composition using the same, and method for curing the same | THREE BOND CO LTD | 2011-07-13 | — | — | CN | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
| CN-101479310-A | Amine imide compound to be activated by irradiation of active energy ray, composition using the same, and method for curing the same | THREE BOND CO LTD (JP) | 2009-07-08 | — | — | CN | disclosed |
| EP-0635490-B1 | Process for the preparation of N-ethylcarbazole | HOECHST AG (DE) | 1996-12-11 | — | — | EP | disclosed |
| US-5393894-A | Process for the preparation of N-ethylcarbazole | CASSELLA AKTIENGESELLSCHAFT (DE) | 1995-02-28 | — | — | US | disclosed |
| US-5393894-A | Process for the preparation of N-ethylcarbazole | CASSELLA AKTIENGESELLSCHAFT (DE) | 1995-02-28 | — | — | US | disclosed |
| EP-0635490-A1 | Process for the preparation of N-ethylcarbazole | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-01-25 | — | — | EP | disclosed |
| EP-0635490-A1 | Process for the preparation of N-ethylcarbazole | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | ICOS, CD47, CD274 | NTRK1 187/4885POLB 3911/4885MAPT 3950/4885 |
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | ICOS, CD47, CD274 | NTRK1 187/4885POLB 3911/4885MAPT 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.